Emerging infectious diseases · 2009 · 361 citations · 27 references
Life SciencesInfectious DiseasesInfectious Disease EpidemiologyMolecular VirologyVirologyAntiviral Drug ResistanceAntiviral ResistanceRespiratory Infectious DiseasesViral EpidemiologyViral GeneticsViral InfectionsInfluenza Antiviral ResistanceInfluenza Antiviral TherapyInfluenza TreatmentMolecular Epidemiology Of VirusesNeuraminidase Inhibitor ResistanceSeasonal Activity CyclesSeasonal Influenza SurveillanceSubgroup Structure
In Europe, the 2007-08 winter season was dominated by influenza virus A (H1N1) circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant influenza viruses A (H1N1) (ORVs) with H275Y mutation in the neuraminidase emerged independently of drug use. By country, the proportion of ORVs ranged from 0% to 68%, with the highest proportion in Norway. The average weighted prevalence of ORVs across Europe increased gradually over time, from near 0 in week 40 of 2007 to 56% in week 19 of 2008 (mean 20%). Neuraminidase genes of ORVs possessing the H275Y substitution formed a homogeneous subgroup closely related to, but distinguishable from, those of oseltamivir-sensitive influenza viruses A (H1N1). Minor variants of ORVs emerged independently, indicating multiclonal ORVs. Overall, the clinical effect of ORVs in Europe, measured by influenza-like illness or acute respiratory infection, was unremarkable and consistent with normal seasonal activity.
27
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Maki Kiso, Keiko Mitamura, Yuko Sakai‐Tagawa et al. · The Lancet · 2004 · 795 citations
Tiffany G. Sheu, Varough Deyde, Margaret Okomo‐Adhiambo et al. · Antimicrobial Agents and Chemotherapy · 2008 · 484 citations · Full text
J. Ives, Jackie Carr, Dirk B. Mendel et al. · Antiviral Research · 2002 · 382 citations
Arnold S. Monto, Jennifer L. McKimm‐Breschkin, Catherine A. Macken et al. · Antimicrobial Agents and Chemotherapy · 2006 · 364 citations · Full text